Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy
Abbreviated Journal Title
J. Am. Chem. Soc.
FOLATE RECEPTOR; IN-VIVO; DRUG-DELIVERY; FOLIC-ACID; INFLAMMATORY; DISEASES; BIOLOGICAL EVALUATION; TUMOR-CELLS; NANOPARTICLES; DESIGN; PROBES; Chemistry, Multidisciplinary
Herein we describe the design and synthesis of a folate doxorubicin conjugate with activatable fluorescence and activatable cytotoxicity. In this study we discovered that the cytotoxicity and fluorescence of doxorubicin are quenched (OFF) when covalently linked with folic acid. Most importantly, when the conjugate is designed with a disulfide bond linking the targeting folate unit and the cytotoxic doxorubicin, a targeted activatable prodrug is obtained that becomes activated (ON) within the cell by glutathione-mediated dissociation and nuclear translocation, showing enhanced fluorescence and cellular toxicity. In our novel design, folic acid acted as both a targeting ligand for the folate receptor as well as a quencher for doxorubicin's fluorescence.
Journal of the American Chemical Society
"Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy" (2011). Faculty Bibliography 2010s. 1847.